We recently demonstrated that Notch1 blockade with a neutralizing antibody we developed, led to reduced cutaneous melanoma cell growth and survival and importantly, reduced tumor growth, and enhanced responses to anti-PD1 [15]. The gene discussed is NOTCH1; the disease is cutaneous melanoma.